WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 531388
Description: AC261066 is a retinoic acid receptor β2 agonist.
MedKoo Cat#: 531388
Chemical Formula: C17H20FNO4S
Exact Mass: 353.1097
Molecular Weight: 353.4084
Elemental Analysis: C, 57.78; H, 5.70; F, 5.38; N, 3.96; O, 18.11; S, 9.07
Synonym: AC261066; AC-261066; AC 261066;
IUPAC/Chemical Name: 4-[4-(2-butoxyethoxy)-5-methyl-1,3-thiazol-2-yl]-2-fluorobenzoic acid
InChi Key: HSAOETBFVAWNRP-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H20FNO4S/c1-3-4-7-22-8-9-23-15-11(2)24-16(19-15)12-5-6-13(17(20)21)14(18)10-12/h5-6,10H,3-4,7-9H2,1-2H3,(H,20,21)
SMILES Code: O=C(O)C1=CC=C(C2=NC(OCCOCCCC)=C(C)S2)C=C1F
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 353.4084 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Trasino SE, Tang XH, Jessurun J, Gudas LJ. A retinoic acid receptor β2 agonist reduces hepatic stellate cell activation in nonalcoholic fatty liver disease. J Mol Med (Berl). 2016 Oct;94(10):1143-1151. PubMed PMID: 27271256; PubMed Central PMCID: PMC5053866.
2: Trasino SE, Tang XH, Jessurun J, Gudas LJ. Retinoic acid receptor β2 agonists restore glycaemic control in diabetes and reduce steatosis. Diabetes Obes Metab. 2016 Feb;18(2):142-51. doi: 10.1111/dom.12590. PubMed PMID: 26462866; PubMed Central PMCID: PMC4948868.
3: Lund BW, Piu F, Gauthier NK, Eeg A, Currier E, Sherbukhin V, Brann MR, Hacksell U, Olsson R. Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist. J Med Chem. 2005 Dec 1;48(24):7517-9. PubMed PMID: 16302793.